Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL290730 | 0.97 | — | — | |
| SCHEMBL27796812 | 0.93 | — | — | |
| Water SCHEMBL11546193 | 0.93 | — | — | |
| Benzene SCHEMBL8598626 | 0.90 | MAOA (0.41) | — | |
| Water SCHEMBL27890637 | 0.90 | — | — | |
| Ethylene SCHEMBL28293069 | 0.90 | — | — | |
| Potassium Chloride SCHEMBL28646771 | 0.89 | GRIN2D (0.35) | — | |
| Cyclopropane SCHEMBL8040928 | 0.88 | — | — | |
| SCHEMBL9094845 | 0.77 | ALDH1A1 (0.39) | — | |
| SCHEMBL17970433 | 0.75 | ALDH1A1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150272934-A1 | USE OF CSE INHIBITORS FOR THE TREATMENT OF CUTANEOUS INJURIES OR CONDITIONS AND SLEEP-RELATED BREATHING DISORDERS | SOVA PHARMACEUTICALS, INC. | 2015-10-01 | — | — | US | claimed |
| EP-2877175-A2 | USE OF CSE INHIBITORS FOR THE TREATMENT OF CUTANEOUS INJURIES OR CONDITIONS AND SLEEP-RELATED BREATHING DISORDERS | Sova Pharmaceuticals, Inc. (US) | 2015-06-03 | — | — | EP | claimed |
| WO-2014018571-A2 | USE OF CSE INHIBITORS FOR THE TREATMENT OF CUTANEOUS INJURIES OR CONDITIONS AND SLEEP-RELATED BREATHING DISORDERS | SOVA PHARMACEUTICALS, INC. (US) | 2014-01-30 | — | — | WO | claimed |
| EP-1948624-B1 | PROCESS FOR THE PREPARATION OF BENZO[E][1,2,4]TRIAZEPIN-2-ONE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2013-10-23 | — | — | EP | claimed |
| EP-4727909-A1 | METHODS AND INTERMEDIATES FOR PREPARING COMPOUNDS | VIIV Healthcare UK (No.5) Limited (GB) | 2026-04-22 | — | — | EP | disclosed |
| WO-2024257009-A1 | METHODS AND INTERMEDIATES FOR PREPARING COMPOUNDS | VIIV Healthcare UK (No.5) Limited (GB) | 2024-12-19 | — | — | WO | disclosed |
| WO-2023215559-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | ARIA PHARMACEUTICALS, INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| EP-2877457-B1 | CYSTATHIONINE-GAMMA-LYASE (CSE) INHIBITORS | SOVA PHARMACEUTICALS INC (US) | 2020-09-23 | — | — | EP | disclosed |
| CN-108473439-A | Pyrazolone derivative as nitroxyl donors | 卡尔迪奥克斯尔制药公司 | 2018-08-31 | — | — | CN | disclosed |
| US-20170327478-A1 | CYSTATHIONINE-GAMMA-LYASE (CSE) INHIBITORS | SOVA PHARMACEUTICALS, INC. | 2017-11-16 | — | — | US | disclosed |
| US-9725426-B2 | Cystathionine-γ-lyase (CSE) inhibitors | SOVA PHARMACEUTICALS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| EP-3096755-A2 | CYSTATHIONINE-(gamma)-LYASE (CSE) INHIBITORS FOR TREATING PAIN | Sova Pharmaceuticals, Inc. (US) | 2016-11-30 | — | — | EP | disclosed |
| EP-1545510-A4 | SUBSTITUTED PHENYLINDOLES FOR THE TREATMENT OF HIV | IDENIX CAYMAN LTD (KY) | 2006-11-15 | — | — | EP | disclosed |
| EP-1545510-A1 | SUBSTITUTED PHENYLINDOLES FOR THE TREATMENT OF HIV | Idenix (Cayman) Limited (KY) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004098609-A1 | BENZOTRIAZEPINE DERIVATIVES AND THEIR USE AS GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 2004-11-18 | — | — | WO | disclosed |
| US-20040180945-A1 | Substituted phenylindoles for the treatment of HIV | ARTICO MARINO (IT) | 2004-09-16 | — | — | US | disclosed |
| WO-2004014364-A1 | SUBSTITUTED PHENYLINDOLES FOR THE TREATMENT OF HIV | IDENIX (CAYMAN) LIMITED (KY) | 2004-02-19 | — | — | WO | disclosed |
| EP-1206482-B1 | METHOD FOR COUPLING, IN SOLUTION, A PEPTIDE WITH AT LEAST ANOTHER COMPOUND AND USES THEREOF | PASTEUR INSTITUT (FR) | 2003-09-24 | — | — | EP | disclosed |
| EP-1206482-A2 | METHOD FOR COUPLING, IN SOLUTION, A PEPTIDE WITH AT LEAST ANOTHER COMPOUND AND USES THEREOF | INSTITUT PASTEUR DE LILLE (FR) | 2002-05-22 | — | — | EP | disclosed |
| WO-2001014408-A2 | METHOD FOR COUPLING, IN SOLUTION, A PEPTIDE WITH AT LEAST ANOTHER COMPOUND AND USES THEREOF | INSTITUT PASTEUR DE LILLE (FR) | 2001-03-01 | — | — | WO | disclosed |